Welcome to our dedicated page for Mirum Pharmaceuticals SEC filings (Ticker: MIRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, orphan-drug exclusivity clauses, and IBAT-inhibitor safety tables can bury the numbers investors need. For Mirum Pharmaceuticals, whose focus on rare cholestatic liver diseases packs every report with dense science, the challenge is even greater. If you have ever searched 鈥�Mirum Pharmaceuticals SEC filings explained simply,鈥� you know how quickly a 300-page document can stall your research.
Stock Titan solves that problem. Our AI reviews each Mirum Pharmaceuticals quarterly earnings report 10-Q filing, flags R&D burn, and delivers concise Mirum Pharmaceuticals earnings report filing analysis. AG真人官方-time alerts surface Mirum Pharmaceuticals Form 4 insider transactions real-time, letting you track Mirum Pharmaceuticals executive stock transactions Form 4 ahead of pivotal data releases. Need leadership-pay details? The Mirum Pharmaceuticals proxy statement executive compensation section lands in plain English. Even Mirum Pharmaceuticals 8-K material events explained arrive minutes after they hit EDGAR.
Everything is here鈥攆rom the Mirum Pharmaceuticals annual report 10-K simplified to day-to-day Mirum Pharmaceuticals insider trading Form 4 transactions鈥攁ll enhanced by understanding Mirum Pharmaceuticals SEC documents with AI. AG真人官方-time updates, expert commentary, and a clean interface let professionals compare segment trends, monitor drug-approval milestones, and spot market-moving disclosures without wading through biotech jargon.
Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals (MIRM), reported both non-derivative and derivative transactions affecting her holdings. The filing shows a sale of 10,000 common shares at $58.00, after which her reported direct beneficial ownership stood at 2,426 shares. On the same date she recorded an acquisition-related entry at a $6.27 price for 10,000 common shares, with a reported beneficial ownership figure of 12,426 shares following that transaction.
An employee stock option with a conversion/exercise price of $6.27 covering 10,000 underlying shares is reported and is stated to be fully vested. The filing notes the sale was executed pursuant to a Rule 10b5-1 plan adopted December 16, 2024, and the reporting person is shown as beneficial owner of 40,000 derivative securities following the reported activity.
Christopher Peetz, Mirum Pharmaceuticals (MIRM) Chief Executive Officer and director, reported option exercise and a planned sale of shares on 08/07/2025. He acquired 40,000 common shares by exercise at a conversion/exercise price of $2.936 per share, and concurrently sold 40,000 common shares under a Rule 10b5-1 plan at a weighted average price of $55.251 (range $55.25鈥�$55.485). The filing notes the 10b5-1 plan was adopted on November 22, 2024, and the related employee stock option is fully vested.
The report lists direct beneficial ownership figures shown after the transactions (reported as 178,641 and 138,641 shares in the non-derivative table) and an indirect holding of 208,570 shares held by The Peetz Family Trust. The filing was submitted by an attorney-in-fact.
Mirum Pharmaceuticals, Inc. (MIRM) 鈥� Form 4 insider transaction filing. SVP & Global Controller Jolanda Howe reported three transactions between 1鈥�3 July 2025.
- 1 Jul 2025: 1,041 restricted stock units (RSUs) converted into an equal number of common shares (Transaction Code M). Post-conversion ownership temporarily rose to 3,467 shares.
- 2 Jul 2025: 564 shares sold at $48.25 (Code S) to cover tax-withholding obligations tied to the RSU vesting.
- 3 Jul 2025: 477 shares sold at $49.08 under a pre-existing Rule 10b5-1 plan adopted 16 Dec 2024.
Following these actions, Howe鈥檚 direct beneficial ownership declined from 3,467 to 2,426 common shares. All 1,041 RSUs from the reported award are now fully settled, leaving no outstanding derivative securities.
The RSU grant vests in three equal annual installments that began on 1 Jul 2023. All reported transactions were executed by a single insider; no joint filings were made.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
